{
    "nctId": "NCT03619044",
    "briefTitle": "The Use of FES-PET Imaging as a Tool to Detect a Possible Reversion of Estrogen Receptor (ER)-\u03b1 Status in Patients With Metastatic Breast Cancer HER2 + and ER\u03b1 Neg Treated With Trastuzumab + Pertuzumab + Taxane.",
    "officialTitle": "The Use of FES-PET Imaging as a Tool to Detect a Possible Reversion of Estrogen Receptor (ER)-\u03b1 Status in Patients With Metastatic Breast Cancer HER2 + and ER\u03b1 Neg Treated With Trastuzumab + Pertuzumab + Taxane.",
    "overallStatus": "TERMINATED",
    "conditions": "HER2-positive Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "OTHER",
    "enrollmentCount": 4,
    "primaryOutcomeMeasure": "The rate of patients with conversion of FES negative lesions in FES positive lesions.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Age \u2265 18 years.\n2. Patient with metastatic breast cancer HER2 + (IHC+++ and/or HER2 amplification in ISH according to ASCO recommendations), ER\u03b1 neg (0% in IHC) and Progesterone Receptor neg (0% in IHC).\n3. Patient eligible according to the investigator for a treatment with trastuzumab + pertuzumab + taxane in the metastatic first line.\n4. Available biopsy of a tumor lesion (archived material) or biopsiable tumor lesion for study (primitive tumor or metastasis other than bone).\n5. OMS \u2264 2.\n6. For non-menopausal patients, use of an effective contraceptive method at entry into the study and for the duration of the study.\n7. Patient affiliated to a Social Health Insurance in France.\n8. Patient must provide written informed consent prior to any study specific procedures.\n\nExclusion Criteria:\n\n1. Any previous treatment for metastatic disease.\n2. Prior adjuvant treatment with anti-HER2 antibodies taken within 6 months.\n3. Patient with isolated hepatic metastasis.\n4. Patient with hemostasis disorders.\n5. Unbalanced Diabetes.\n6. Patient with usual formal contraindication to PET/TDM Imaging.\n7. Patient who has already started trastuzumab + pertuzumab + taxane treatment.\n8. Pregnant or breastfeeding women.\n9. Any psychological, familial, geographical or sociological condition which does not allow to respect the medical follow-up and/or compliance to study procedure.\n10. Patient protected by law.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}